| Hazard Information | Back Directory | [Description]
ST-198 is anantagonist of dopamine D3 receptor. | [Uses]
ST 198 is an orally active D3R antagonist. ST 198 can block the expression of nicotine-induced CPP at doses selective for D3R. ST 198 can be used for the research of neurological disease[1]. | [in vivo]
ST 198 (p.o.; 3, 30, 100 mg/kg) inhibits the expression of nicotine CPPs[1]. | Animal Model: | Rats[1]. | | Dosage: | 3, 30, 100 mg/kg | | Administration: | p.o | | Result: | Displayed nicotine-induced CPP. |
| [References]
[1] Le Foll B, et al. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology. 2005;30(4):720-730. DOI:10.1038/sj.npp.1300622 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|